Complement C1 Esterase Inhibitor Levels Linked to Infections and Contaminated Heparin-Associated Adverse Events by Zhou, Zhao-Hua et al.
Complement C1 Esterase Inhibitor Levels Linked to
Infections and Contaminated Heparin-Associated
Adverse Events
Zhao-Hua Zhou
1, Trina Chen
1, Kamalpreet Arora
1, Kenneth Hyams
2, Steven Kozlowski
1,2*
1Division of Monoclonal Antibodies, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland,
United States of America, 2Office of Biological Products, Office of Pharmaceutical Sciences, Center for Drug Evaluation and Research, Food and Drug Administration, Silver
Spring, Maryland, United States of America
Abstract
Activation of kinin-kallikrein and complement pathways by oversulfated-chondroitin-sulfate (OSCS) has been linked with
recent heparin-associated adverse clinical events. Given the fact that the majority of patients who received contaminated
heparin did not experience an adverse event, it is of particular importance to determine the circumstances that increase the
risk of a clinical reaction. In this study, we demonstrated by both the addition and affinity depletion of C1inh from normal
human plasma, that the level of C1inh in the plasma has a great impact on the OSCS-induced kallikrein activity and its
kinetics. OSCS-induced kallikrein activity was dramatically increased after C1inh was depleted, while the addition of C1inh
completely attenuated kallikrein activity. In addition, actual clinical infection can lead to increased C1inh levels. Plasma from
patients with sepsis had higher average levels of functional C1inh and decreased OSCS-induced kallikrein activity. Lastly,
descriptive data on adverse event reports suggest cases likely to be associated with contaminated heparin are inversely
correlated with infection. Our data suggest that low C1inh levels can be a risk factor and high levels can be protective. The
identification of risk factors for contact system-mediated adverse events may allow for patient screening and clinical
development of prophylaxis and treatments.
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Introduction
All medications have the potential to produce adverse events
(AEs) [1] and such adverse events lead to significant morbidity and
mortality [2,3]. Between late 2007 and early 2008 there was an
increase in heparin-associated AEs. According to the Centers for
Disease Control and Prevention (CDC) and the Food and Drug
Administration (FDA), these AEs resembled anaphylaxis and
occurred in hundreds of patients. Associated symptoms and signs
included hypotension, facial swelling, tachycardia, urticaria,
nausea and in some cases death [4,5,6,7,8]. A ‘‘heparin-like’’
contaminant, oversulfated chondroitin sulfate (OSCS), found in up
to 30% of suspect lots of heparin, was associated with the AEs
[5,6]. Despite the likely distribution of millions of contaminated
heparin doses [4] only hundreds of adverse events were reported
[8]. Even with potential under-reporting, this suggests the majority
of patients who received the same lots of contaminated heparin did
not experience an adverse event. Thus, exposure to OSCS
required additional co-factors or patient susceptibilities to cause
clinical reactions.
The major symptoms of this cluster of heparin associated AEs
are characteristic of anaphylaxis [6]. Anaphylaxis includes
immunologic (e.g., IgE-mediated or immune complex-mediated)
and non-immunologic mechanisms (e.g., mediated through other
activators of mast cell degranulation) that cause clinically
indistinguishable reactions [9]. Signs and symptoms of anaphylaxis
vary, but cutaneous features (urticaria, angioedema, and erythe-
ma) and decreased blood pressure are the most common overall
[9]. Although the AEs associated with contaminated heparin often
included hypotension, gastrointestinal symptoms were also com-
mon and urticaria was relatively rare [4,8]. Thus, IgE-mediated
allergic reactions or mast cell degranulation were unlikely
explanations for the heparin-associated adverse events [10]. IgG-
mediated hypersensitivity reactions were also unlikely explanations
due to the rapid onset of the AEs [10]. However OSCS activated
the contact system enzyme kallikrein leading to amidolytic activity
in vitro, and OSCS caused a hypotensive response in pigs [6].
While this study of the contact system provided a potential
biologic link between the contaminant and the contact system-
associated anaphylactoid reactions seen in affected patients, some
animals injected with OSCS did not develop any clinical signs [6].
This is not unexpected as the majority of patients that received
contaminated lots of heparin did not develop any clinical
symptoms. Apparently, OSCS alone does not necessarily lead to
development of symptoms. Since the contact system is a major
target of OSCS and a likely cause of the clinical responses,
susceptibility factors could include components and/or regulators
of the contact system.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34978We hypothesized that the C1 esterase inhibitor (C1inh) level is a
key factor in determining the outcome of OSCS exposure. This is
based upon several facts. First, C1inh, an alpha-2-globulin and
member of the serpin family of serine protease inhibitors, is a
major inhibitor for both the complement classical pathway and
contact system [11,12,13]. While C1inh is the only inhibitor of
C1r and C1s, the classical complement pathway proteases [14,15],
it also regulates intrinsic coagulation via inactivation of factor XIa
[16,17]. Importantly in our context, C1inh regulates kinin
generation via inactivation of factors XIIa and plasma kallikrein.
Second, many of the reported OSCS-contaminated heparin AE
reactions were similar to reactions caused by C1inh-deficiency,
i.e., hereditary angioedema (HAE) [12,18,19]. In addition to the
inherited C1inh-deficiency, an acquired C1inh-deficiency can also
occur due to consumption of C1inh in the situations of a sudden or
continuous activation of the complement pathways leading to a
transient or prolonged decrease in C1inh levels [11,18,20,21].
Acquired C1inh deficiency is often associated with lymphoprolif-
erative disease and/or C1inh reactive autoantibodies [11]. C1inh
levels may also vary in response to a variety of situations, such as
infection, inflammation and autoimmune diseases (e.g.,systemic
lupus erythematosus or SLE) [22,23]. Third, knocking out the C1
inhibitor gene to generate homozygous- and heterozygous- C1inh
deficient mice, revealed increased vascular permeability and
angioedema mediated by bradykinin via the bradykinin B2
receptor (Bk2r) [19].
If C1inh is a key factor that contributed to the OSCS linked
adverse events, then we would predict that higher or lower levels of
C1inh in the plasma should have an enhancing or inhibitory
impact, respectively, on the OSCS-induced contact system
activation. In this study, several types of analyses were used to
test this hypothesis.
Methods
Materials
OSCS-contaminated heparin lots and un-contaminated heparin
lots were obtained by the FDA from Baxter Healthcare (1000 U/
ml or 5000 U/ml in 10 ml and 30 ml vials) [7]. Synthetic
oversulfated chondroitin sulfate (OSCS) was obtained from the
Division of Pharmaceutical Analysis, FDA. St. Louis, MO.
Chondroitin sulfate A (CSA) was purchased from Sigma (St.
Louis, MO). Purified human complement C1 esterase inhibitor
(C1inh) was purchased from Sigma. Normal human plasma and
purified human prekallikrein was purchased from Innovative
Research (Novi, Michigan). Purified human Factor XIIa and
Factor XII deficient plasma supplied by Hyphen BioMed (France)
was purchased through Innovative Research. Recombinant
human complement components C1r and C1s were purchased
from R&D Systems (Minneapolis, MN). Anti-complement com-
ponent C1 inhibitor mouse monoclonal antibody was obtained
from the AntibodyShop (Denmark), purified peroxidase-conjugat-
ed goat anti-human C1inh IgG was purchased from Cedarlane
laboratories (Canada). Protein A/G-Sepharose was purchased
from BioVision (Mountain View, CA). PE anti-human comple-
ment C3 monoclonal antibody was purchased from Cedarlane
laboratories.
Human Plasma Samples
Human plasma samples from patients and normal individuals
were obtained from Bioreclamation, Inc. (Hicksville, NY). All the
human samples were de-identified in such a manner that subjects
could not be identified, directly or through identifiers linked to the
subjects. Other than the clinical descriptor (e.g. sepsis), only age
and gender of the person were collected and recorded (FDA
RIHSC Protocol #10-054D).
Affinity Depletion of C1inh from Human Plasma
16 sterile micro tubes (Sarstedt Inc., Newton, NC) each with
0.5 ml Protein A/G Sepharose beads were washed with cold PBS
twice and centrifuged at 10,000 g. To half of the tubes (designated
as ‘‘Anti-C1inh beads’’) 150 mg monoclonal mouse anti-human
C1inh IgG and 1 mg of goat anti-human C1inh polyclonal IgG
were added while to the other half of the tubes (designated as
‘‘Control beads’’) either same amount of PBS or irrelevant goat
IgG was added. The tubes were incubated with rotation at 4uC for
20 minutes followed by three washes with cold PBS. Then 1 ml of
normal human plasma and of Factor XII-deficient human plasma
were added to the ‘‘Anti-C1inh beads’’ or ‘‘Control beads’’ tubes.
The tubes were mixed by rotation for 20 minutes at 4uC, followed
by centrifugation at 10,000 g. The bead-treated plasma samples
were then transferred to a second tube with the same beads and
the steps were again repeated for a total of four rounds resulting in
control human plasma, C1inh-reduced plasma, Factor XII-
deficient plasma and C1inh2/FXII- double deficient plasma.
The plasma was then aliquoted and frozen at 280uC. C1inh levels
in the plasma were determined by ELISA and more than 98% of
C1inh antigen was removed by this method. The above described
plasma treatment did not induce ‘‘cold activation’’ and kallikrein
level was within base line as determined by s-2302.
Kallikrein Amidolytic Activity Assay
Normal human plasma, C1inh-deficient plasma, factor XII-
deficient plasma or C1inh2/FXII double deficient human plasma
were treated with various concentration of OSCS, OSCS-
contaminated heparin, uncontaminated heparin, and chondroitin
sulfate A for 10 minutes at 37uC. The samples were then diluted
1:10 with 50 mM Tris-HCl and an equal amount of s-2302
chromogenic substrate (H-D-Pro-Phe-Arg-p-nitroaniline
[pNA]?2HCl, DiaPharma Group, Inc., West Chester, Ohio) was
added. The samples were then incubated at 37uC for 10 minutes,
followed by the addition of 20% acetic acid to stop the reaction
and the spectrophotometric optical density (OD) was determined
at 405 nm. It is worthy to mention that s-2302 is also substrate for
FXa, FXIa, FXIIa and thrombin, but assay conditions as
described above can make the substrate highly specific for
kallikrein (100% reactivity for plasma kallikrein vs. ,3,10% for
other factors).
Bacteria Treatment of Plasma and C1inh Deposition
Gram-negative E. coli BL21 bacteria were cultured in Luria-
Bertani (LB) broth, until an OD600 of 0.3 was reached. Then the
bacteria were washed thoroughly with cold PBS and 2610
8
bacteria were incubated with 50 mg of monoclonal polyreactive
IgM [24] at room temperature for 30 minutes and washed with
cold PBS. Then the antibody coated bacteria were added to 100 ml
of normal human plasma for 5 minutes at 37uC followed by
centrifugation at 10,000 g for 2 minutes. The plasma was then
removed and diluted with PBS and the C1inh levels were tested by
ELISA. To evaluate the C1inh deposited on bacteria, the bacteria
were washed twice with cold PBS, followed by the addition of goat
anti-human C1inh IgG-peroxidase, incubation at 4uC for
30 minutes, four washes with cold PBS, centrifugation and the
addition of 1 ml ABST substrate. Samples were then incubated at
37uC for 20 minutes, centrifuged again, and the supernatants were
read at 405 nm for OD. Bacteria that had not been treated with
plasma were used as a negative control. The bacterial treatment
C1 Inhibitor and Risk of Contaminated Heparin
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substrate s-2302.
OSCS-Induced Kallikrein Kinetics and Dose Response
Normal and C1inh-deficient human plasma that had been
treated or not treated with polyreactive antibody were mixed with
various concentrations of OSCS as indicated. After incubation for
10 minutes at 37uC, samples were diluted with 50 mM PH 7.8
Tris-HCl and s-2302 substrate was added with continued
incubation and shaking for 10 minutes at 37uC, followed by the
addition of 20% acetic acid to stop the reaction. The OD at
405 nm was measured to determine the kallikrein activity. For
OSCS-induced kallikrein kinetics, 25 mg/ml of OSCS was added
to normal plasma and C1inh-deficient plasma at different time
points. Then s-2302 was added and incubated at 37uC for
10 minutes, immediately followed by the addition of 20% acetic
acid to stop the reaction. Sample OD at 405 nm was measured.
Competition for C1inh by C1r, C1s and FXIIa
To optimize the dose of C1inh for the inhibition of FXIIa,
different doses of C1inh (from 2.5 ng to 1000 ng) were incubated
with 1 ng of FXIIa in 20 ml of 50 mM Tris-HCl buffer at 37uC for
5 minutes, then added into 1 mg purified prekallikrein (in 10 ml
Tris-HCl) and the incubation continued at 37uC for 1 minute.
Then 20 ml Tris-HCl and 50 ml s-2302 were added and incubated
at 37uC for 10 minutes followed by the addition of 50 ml acetic
acid to stop reaction. Kallikrein activity was evaluated by reading
the OD at 405 nm. For the competition assay, 1 mgo f
prekallikrein was added with 0.5 mg of C1inh, a mixture of
0.5 mg C1inh with 0.5 mg C1s and 0.5 mg C1r, or 50 ml Tris-HCl
buffer, and incubated at 37uC for 5 minutes. Then 1 ng of FXIIa
in 10 ml Tris-HCl buffer was added and the samples incubated at
37uC for another 5 minutes. 50 ml s-2302 was then added and the
samples were incubated at 37uC for 10 minutes. The reaction was
stopped by the addition of 50 ml 20% acetic acid and the OD at
405 nm was measured.
Functional C1inh in plasma
Functional C1inh was determined by a chromogenic assay using
the Technochrom C1-inh kit (DiaPharma Group, Inc., West
Chester, Ohio) according to the manufacture’s instruction with
some modifications. Briefly, all the reagents provided in the kit
were reconstituted and prepared; all the plasma samples and
reference standard were diluted with Sample Buffer A at a ratio of
1:11 and put on ice. 50 ml diluted plasma samples and standard
reference were added into 96-well polystyrene plates with
duplication and kept on ice. Then 25 ml/well C1s was added,
followed by incubation at 37uC for 5 minutes. Plates were then
again put on ice, 125 ml of substrate C1-1 was then added to each
well and the plates were incubated at 37uC for 3 minutes. Plates
were placed on ice and 50 ml/well of 50% acetic acid was added
immediately. The OD at 405 nm was read on a Perkin Elmer
Victor Multilabel Plate Reader (Waltham, Massachusetts). Func-
tional C1inh levels were calculated using the standard reference
curve.
Statistical Analysis
Duplicate samples were evaluated and experiments were
repeated at least three times except as noted. Data are presented
as mean or mean 6 standard error of the mean. For patient
samples, data are expressed as mean of duplicates for each sample
and mean 6 SD for the group. The Pearson product-moment
correlation coefficient was used to evaluate the correlation
between variables. Difference between groups and all paired
comparisons were subjected to unpaired or two-tailed Student’s t
tests, respectively. Significance was set at a p value of less than
0.05. All differences noted in experiments with multiple paired
comparisons were significant at a p value of ,0.01.
Adverse Event Report Descriptions
Adverse event reports submitted to the FDA were evaluated
using Empirica Signal 7.2 software. Queries to count cases used
CBAERS BestRep (S+C) data. This data set contains the best
representative cases, includes suspect as well as concomitant drugs
and has duplicate removal. All queries were limited to cases where
the active ingredient heparin was reported as a suspect or
concomitant drug and the term ‘‘dialysis’’ was present in the
narrative. This set of case reports was divided into two groups.
One group had event dates from 11/1/2007 to 3/31/2008, the
timeframe of the OSCS contamination. The second contained all
the other reports from 1/1/2000 to 12/31/2010 as a control
group. Additional queries were then limited by other reported
events or medications. Event terms used in these queries were
Medical Dictionary for Regulatory Activities (MedDRA) Preferred
Terms (PT) or High Level Group Terms (HGLT) terms and are
described in Appendix S1. Drug terms used in the queries are
terms based on the Anatomical Therapeutic Chemical (ATC)
classification system and also described in Appendix S1.
Results
C1 inhibitor regulates OSCS-induced kallikrein activity
To determine if C1inh plays any role in OSCS-induced
kallikrein amidolytic activity, normal human plasma and the same
plasma depleted of C1inh were incubated with OSCS and then
kallikrein activity was compared using a chromogenic assay. As
shown in figure 1a, OSCS induced kallikrein activity in normal
plasma and when C1inh was depleted, kallikrein activity was
dramatically increased. Kallikrein activity by OSCS in both
normal and C1inh-deficient plasma was FXII-dependent, since
the depletion of FXII alone or both FXII and C1inh together led
to an absence of kallikrein activity. A control glycosaminoglycan
(GAG), chondroitin sulfate A (CSA) did not induce kallikrein
activity independent of C1inh or FXII levels (Figure 1a). The data
also indicate the experimental depletion of FXII and C1inh did
not induce additional kallikrein activity in the controls. The
inhibitory role of C1inh in the OSCS-induced kallikrein activity
was confirmed by adding highly purified C1inh into C1inh-
depleted plasma before the addition of OSCS. Kallikrein activity
was totally inhibited with the addition of 200 mg/ml of C1inh
(Figure 1b).
C1 inhibitor can be depleted by complement activation
leading to increased OSCS-induced kallikrein activity
To rule out an effect on kallikrein activity specific to affinity
depletion of C1inh, we evaluated the effect of C1inh consumption
through a biologically relevant pathway, bacterial activation of
complement [24]. Complement C1 and C3 fixation on bacteria
were detected by immunostaining and FACS analysis (data not
shown), and there was significant deposition of C1inh on bacterial
surfaces after incubation with plasma (Figure 2a). As expected
from the observed C1inh deposition, the plasma C1inh level was
decreased in bacteria-treated plasma (Figure 2b). While the
bacterial treatment alone did not generate kallikrein activity,
OSCS-induced kallikrein activity was strikingly increased in the
bacteria-treated plasma as compared to non-bacteria treated
control plasma (Figure 2c). Kallikrein activity induced by OSCS
C1 Inhibitor and Risk of Contaminated Heparin
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kallikrein activity induced by synthetic OSCS. A PBS control,
CSA and uncontaminated-heparin did not induce kallikrein
activity in either bacteria-treated or untreated plasma (Figure 2c).
The addition of C1inh completely inhibited the OSCS-induced
kallikrein activity in both normal plasma and bacteria-treated
plasma (Figure 2d).
Kinetic and dose response of OSCS-induced kallikrein
activity
A kinetic study showed that OSCS-induced kallikrein activity
reached a peak within 10 minutes in C1inh-depleted plasma while
the OSCS-induced kallikrein activity took 15 minutes to peak in
normal plasma (Figure 3a). Kallikrein activity was reduced to half-
maximal levels in approximately 10 minutes in normal plasma
while a similar reduction took more than 30 minutes in C1inh-
reduced plasma. Thus, the kinetics as well as the levels of kallikrein
activity were impacted by C1inh depletion. The more rapid
induction, higher levels and longer duration of kallikrein activity
observed in the C1inh-depleted plasma suggest an earlier, higher
and longer exposure to kallikrein products, such as bradykinin.
Bradykinin (BK) or related molecules are considered likely
mediators of the OSCS contaminated heparin-induced clinical
symptoms, such as hypotension and gastrointestinal symptoms
[25].
The dose response of OSCS was similar in both normal plasma
and C1inh-depleted plasma with increases in kallikrein activity
occurring at levels above 1 mg/ml; however, the magnitude of
kallikrein activity was higher in C1inh-depleted plasma (Figure 3b
and 3c).
After a robust increase, kallikrein activity remained relatively
flat within a broad range (5 to 150 mg/ml) of OSCS concentra-
tions. This finding is consistent with the observation of the CDC
study [4] that no major difference in symptoms was noted between
lots above and below 20% contaminant. Of note, a prior study
using AERS data [8] indicated that a lot with a low concentration
of OSCS (,3%) was less likely to be associated with a time-to-
event of 10 minutes or less in selected cases.
The addition of antibody coated bacteria to plasma increased
the magnitude of the OSCS induced kallikrein activity in both
normal (Figure 3b) and C1inh depleted plasma (Figure 3c). The
increased magnitude of OSCS induced kallikrein activity in C1inh
depleted plasma may be due to further depletion of C1inh through
complement activation although other bacterial effects are
possible.
Complement components C1r and C1s compete with
FXIIa for C1inh interaction
To confirm the role of C1inh consumption in the above
experiments, a simplified model with purified proteins was used to
determine if the interaction of complement components C1r and
C1s with C1inh will have any impact on the contact system
component, activated FXII (FXIIa). A mixture of purified plasma
prekallikrein and FXIIa generate kallikrein as shown in figure 4.
The kallikrein activity was dependent on the level of prekallikrein
(Figure 4a) and FXIIa (Figure 4b). Pre-incubation of C1inh with
FXIIa has a dose-dependent inhibition on the FXIIa activation of
prekallikrein into kallikrein (Figure 4c). This inhibition of FXIIa by
C1inh was blocked by the addition of C1r and C1s to C1inh
(Figure 4d). This finding supports complement consumption of
C1inh as the mechanism for the increased susceptibility of
bacteria-treated plasma to OSCS induced kallikrein activation.
Plasma of patients with higher C1inh levels exhibited
lower OSCS-induced kallikrein activity
To check if there is any relationship between OSCS-induced
contact system activation and the level of C1 inhibitor in patient
populations, OSCS was added to plasma samples from normal
individuals and patients with sepsis. Although C1 inhibitor levels
Figure 1. C1 inhibitor regulates OSCS-induced kallikrein activity. (A) Normal human plasma, plasma depleted of C1 inhibitor, plasma
depleted of factor XII, and plasma depleted of both C1 inhibitor and factor XII, were incubated with chondroitin sulfate A (CSA) or over sulfated
chondroitin sulfate A (OSCS). The effect of kallikrein amidolytic activity was assessed by the addition of the s-2302 chromogenic substrate. (B) OSCS-
induced kallikrein activity was totally inhibited by addition of 200 mg/ml of C1 inhibitor. At least three independent experiments were completed with
duplicate samples for the assay.
doi:10.1371/journal.pone.0034978.g001
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complement in vitro, in vivo C1inh levels can increase due to
elevated C1inh synthesis in response to infections [26]. As shown
in figure 5a, OSCS-induced kallikrein activity was significantly
lower in plasma from septic patients than in plasma of normal
individuals. This suggested an overall increase in C1inh levels in
sepsis and in some studies on sepsis, C1-inh levels were increased
depending on the clinical state of the patients [27,28,29]. C1 inh
levels were evaluated in our samples by measuring C1 inh function
rather than C1 inh antigen since functional C1 inh is more
relevant for adverse events [23]. We also observed a significant
difference of the average functional C1inh level between normal
plasma samples and septic patient samples. The average normal
plasma C1inh level was 130% of the reference standard and the
average septic plasma C1inh level was 175% of the reference
standard. The large diversity of the functional C1inh level within
samples of both groups indicates C1inh level varies among
individuals and depends on the pathophysiological status of
patients. C1inh levels in septic patients was as low as ,20% or
as high as 300% of the reference standard (Figure 5b).
Figure 2. Bacteria incubation consumes C1 inhibitor and increases OSCS-induced kallikrein activity. (A) Natural antibody-coated E. coli
BL21 bacteria were incubated with human plasma at 37uC, washed by PBS, and the level of C1 inhibitor deposited on the bacteria was determined by
addition of horseradish peroxidase-conjugated anti-C1 inhibitor antibody and then developement with ABTS substrate as described in the Materials
and Methods. (B) An ELISA assay showed decreased C1 inhibitor levels in plasma treated with antibody-coated E. coli BL21 bacteria. (C) OSCS and
OSCS-contaminated heparin induced kallikrein activity were increased in plasma treated with antibody-coated bacteria as compared to untreated
plasma. PBS, CSA or uncontaminated heparin did not induce kallikrein activity in either plasma. (D) Kallikrein activity in plasma treated with or
without antibody-coated E. coli BL21 bacteria, C1 inhibitor (200 mg/ml), or OSCS (25 mg/ml) was measured. Data shown were representative of three
independent experiments.
doi:10.1371/journal.pone.0034978.g002
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depletion of C1inh in very early infection followed by a rapid
increase with upregulated C1inh synthesis. If the patient
deteriorates C1 inh levels may again decrease. Nujiens et al
demonstrated that, despite elevated antigenic levels of C1 inh,
some patients with sepsis have increased levels of inactivated
C1 inh and relative functional C1inh deficiency [23]. This
suggests further evaluation of inactivated C1 inh in prognosis
and C1 inh in treatment of deteriorating patients. However a
number of studies besides our own have observed increased
functional C1 inh activity in subgroups of septic patients
[27,28,29]
Since the differences in functional C1inh levels across the
sample populations did not fully explain the pattern of OSCS-
induced kallikrein activity observed, we evaluated the relationship
between OSCS-induced kallikrein activity and functional C1inh in
each sample. This evaluation demonstrated a significant negative
relationship between C1inh functional activity and OSCS-induced
kallikrein activity with an R of 20.413 (Figure 5c). Although the
data showed a lower functional C1inh index is generally related to
Figure 3. OSCS kallikrein activation kinetics and dose response. (A) Kinetics of kallikrein activation in normal plasma and C1inh-depleted
plasma with the addition of 25 mg/ml of OSCS. Kallikrein activity was also determined in (B) normal human plasma and (C) C1inh-depleted plasma
with different doses of OSCS. The OSCS dose response was also evaluated with plasma samples treated with antibody-coated bacteria. Experiments
were repeated independently twice. Duplicate samples were used in panel A.
doi:10.1371/journal.pone.0034978.g003
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value and outlier points suggest there are other potential factors,
such as Factor XII. Levels of Factor XII and prekallikrein have
been shown to decrease in some septic patients [27,29]. However,
these results suggest the level of C1inh is likely to be an important
factor in patient susceptibility to OSCS and there may be enough
variability in C1inh levels to impact the clinical outcome of OSCS
exposure.
A lower frequency of adverse events reports was
associated with infection during the OSCS contamination
timeframe
Although in rare patients sepsis was associated with low levels of
functional C1 inhibitor, in general C1inh levels in the septic
plasma were higher, and OSCS-induced kallikrein activity was
lower in the septic patient samples. To look for a negative
correlation between infections and OSCS-mediated adverse
Figure 4. Complement components C1r and C1s compete with FXIIa for C1inh. Kallikrein activity of (A) different doses of prekallikrein
incubated with a fixed dose (1 ng) of FXIIa; (B) a fixed dose (0.5 mg) of prekallikrein incubated with different doses of FXIIa; (C) different doses of C1inh
premixed with a fixed dose (1 ng) of FXIIa before combining with prekallikrein (1 mg). (D) Kallikrein activity of 0.5 mg of prekallikrein incubated with
different combinations of FXIIa, C1inh and C1r/C1s. Experiments were repeated independently at least three times. Duplicate samples were used in
panels C and D.
doi:10.1371/journal.pone.0034978.g004
C1 Inhibitor and Risk of Contaminated Heparin
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of heparin contamination with other adverse event reports
(Table 1) as described in the Materials and Methods. There was
a very large increase in rate of adverse event reports during the
timeframe of OSCS contamination. As expected, the frequency of
events associated with the contaminant, hypotension and gastro-
intestinal symptoms, more than doubled during this period.
Although the overall rate of reporting infection and sepsis was not
that different between the groups, when the groups were filtered
for either hypotension or gastrointestinal symptoms, signs
associated with contaminated heparin exposure, infections and
sepsis were less frequent during the timeframe of OSCS
contamination. Of note, for cases reporting gastrointestinal
symptoms, sepsis was less than half as frequent during the OSCS
contamination timeframe. Another measure of infection was the
use of anti-infective medications. Use of anti-infectives was far less
likely to be reported with adverse events during the OSCS
contamination timeframe. This decreased frequency of reporting
was also observed when cases were filtered for either hypotension
or gastrointestinal symptoms and when a slightly different set of
anti-infective search terms were used. The relative differences in
frequency between infections and anti-infectives may relate to the
severity and nature of the infections. Those relative differences
decrease when the data is filtered for hypotension or gastrointes-
tinal symptoms.
Since the mechanism that links elevated kallikrein activity to the
observed symptoms had been postulated to be the generation of
kinins, such as BK [25], any factor that increases the levels or
prolongs the duration of BK might impact the risk of OSCS
exposure. ACE inhibitors (ACEi) can increase the levels and
prolong the duration of BK by decreasing BK degradation [25].
To evaluate this, we compared the frequency of reported ACEi use
during the period of OSCS contamination to the control period.
No increase in ACEi use was noted during the time period of the
OSCS contamination. Only very small differences in reported
ACEi use were observed if the data were filtered for either
hypotension or gastrointestinal symptoms.
As passive adverse event reporting has many limitations, there
are alternative explanations for any unobserved or observed
differences in frequencies. To better understand the limits of these
observations, a number of control medications and events were
also evaluated. The frequency of reports with angiotensin II
antagonists, drugs with some mechanistic similarity to ACEi also
did not notably change during the time period of OSCS
contamination. There was also no notable change in the reporting
of statin use but there was a small decrease in the reporting of
Figure 5. OSCS-induced kallikrein activation in patient plasma samples. (A) OSCS-induced kallikrein activation and (B) functional C1inh
levels in plasma samples from normal individuals (n=40) and from patients with septic shock (n=32). (C) The relationship of OSCS-induced kallikrein
activity and functional C1inh levels using the same samples. The error bars correspond to mean 6 SD for each patient group. The correlation
coefficient r=20.413 indicates a negative association between functional C1inh levels and OSCS-induced kallikrein activation. Data shown here were
representative of three independent experiments.
doi:10.1371/journal.pone.0034978.g005
Table 1. Characteristics of AE associated with Heparin & Dialysis 2000–2010.
All (No Filter) Hypotension GI symptoms
Characteristic
All except 11/
2007–3/2008
11/2007–3/
2008
All except 11/2007–3/
2008
11/2007–3/
2008
All except 11/2007–3/
2008
11/2007–3/
2008
AE Case Reports
All 1585 817 327 381 308 426
Rate/month 12.5 163.4 2.6 76.2 2.4 85.2
Contact System Sx
Hypotension 20.6% 46.6%
Gastrointestinal Sx 19.4% 52.1%
Infections
Infections 28.7% 32.4% 48.3% 39.6% 48.4% 32.2%
Sepsis-Septic 13.8% 14.9% 29.7% 24.1% 28.9% 13.8%
BK Metabolism
ACE inhib. 22.5% 21.5% 24.2% 25.7% 25.6% 27.5%
Anti-infectives
Antiinfectives 44.5% 21.7% 39.8% 27.6% 37.3% 20.0%
Antibact./Antibiot. 41.1% 20.8%
Control Drugs
ATii antagon. 9.7% 8.2%
Statins 25.4% 24.8%
Diabetes Meds 29.9% 25.9%
Control Events
HIT 5.9% 6.5%
Myopathy-Myolysis 2.8% 2.9%
doi:10.1371/journal.pone.0034978.t001
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topenia and a variety of myopathies did not have a notable change
in frequency during the period of OSCS contamination. This
finding makes it less likely that the observed decreases in reporting
of infections and anti-infective use during the time period of OSCS
contamination are due to dilution of reported clinical problems.
Discussion
The adverse events associated with OSCS contaminated
heparin have been linked to kallikrein activation. Although
OSCS-driven increases in anaphylactic toxins C3a and C5a have
also been demonstrated in vitro, OSCS-driven kallikrein activation
has been shown in both in vitro and in vivo studies [6]. Pigs treated
with OSCS also developed hypotension, a predominant feature of
the adverse events seen in OSCS exposed patients. Factor XIIa
was also shown to be important in kallikrein activation by OSCS
[6]. OSCS was additionally shown to lead to bradykinin
generation [25]. Bradykinin is a 9-amino acid proinflammatory
peptide that can mediate pain, potent vasodilation and increased
vascular permeability, [25,30] leading to accumulation of fluid in
the interstitium. These biological effects can cause clinical
symptoms, including gastrointestinal symptoms such as nausea,
vomiting, diarrhea, abdominal pain and lower blood pressure
[8,10,25,30,31]. This supports a role for the contact system in
contaminated heparin adverse events.
Of note, in the Kishimoto study [6] not all the exposed animals
exposed to OSCS or contaminated heparin developed hypoten-
sion. This is not surprising since the vast majority of patients who
received contaminated heparin lots did not report adverse events
[4,8]. It is important to understand what factors may have altered
patient susceptibility to OSCS and factors that influence levels of
BK would be likely candidates.
Factors that can influence BK levels are diagramed in figure 6;
all of the listed factors may play a role in susceptibility to OSCS.
OSCS can facilitate FXIIa conversion of pre-kallikrein (PK) to
kallikrein, which is a pivotal factor in contact system activation
[10,31]. OSCS has been shown to bind FXIIa as well as FXII and
may enhance conversion of FXII to FXIIa as well as stabilize the
complex of FXIIa and PK [31]. This increases FXIIa conversion
of pre-kallikrein into kallikrein and kallikrein can then proteolyt-
ically cleave high molecular-weight kininogen (HMWK) into
bradykinin (BK). C1 inhibitor has been shown to be the major
inhibitor of FXIIa and an important inhibitor of kallikrein [32].
The critical role of C1 inhibitor in blocking two key mediators of
BK generation suggests that it is an important factor in OSCS-
mediated adverse events. OSCS may also have a direct effect on
C1inh, as other glycosaminoglycans have been demonstrated to
bind C1inh and impact C1inh functionality [14]. Our results
support a key role of C1 inhibitor in OSCS associated adverse
events. We found that C1inh regulates the OSCS-induced FXII-
dependent kallikrein activity. OSCS-induced kallikrein activity
was dramatically increased after depletion of C1inh from plasma.
The addition of C1inh completely attenuated OSCS-induced
kallikrein activity. Plasma from patients with septic shock patients
had a higher average C1inh level and exhibited lower average
OSCS-induced kallekrein activity. Plasma from patients with
lower levels of C1inh had higher OSCS-induced kallikrein activity.
The CDC study [4] suggested a high frequency of drug allergy
(mostly antibiotics) in patients with OSCS-mediated adverse
events. We only observed a small increase in OSCS-mediated
kallikrein activation in those samples as compared to normal
plasma (data not shown)
To better understand the relationship between adverse events,
infection and thus C1inh, we evaluated adverse event reports
associated with heparin and dialysis. Reports of the expected
symptoms of OSCS-contaminated heparin were less likely to be
associated with infection and sepsis during the time period of
OSCS contaminated heparin. In addition, reports of anti-infective
use were less frequent during the time period of OSCS-
contaminated heparin. The lower use of antiinfectives was even
more striking than the lower rates on infection. This may indicate
that more serious infections were even less likely to be associated
with OSCS-mediated adverse events. However, the possibility that
specific antibiotics were protective independent of infection was
considered. Although unlikely, the high rate of antibiotic allergies
observed by the CDC study [4] could reflect a lower likelihood of
specific antibiotic use by allergic patients. Thus we evaluated
whether the decreased use of antibiotics was limited to one class of
drugs. Although the decreased reporting of different antibiotic
classes was variable, it was seen across multiple classes making a
highly specific protective effect less likely (data not shown).
The evaluation of adverse event reports has a number of
limitations, as they represent passive reports with the challenges of
inconsistent reporting and reporting that lacks essential details [8].
Public knowledge of a product recall, such as occurred with
heparin, stimulates increased reporting of adverse events.
Although a much higher rate of reporting may be seen for both
related and unrelated events, the increased reporting could
potentially dilute out some other adverse events. This could lead
to an artificial reduction in the relative reporting of events such as
infections. We had a number of controls to indicate that the
reductions in frequency we observed were unlikely to be spurious.
Reported control events were not reduced in frequency and
although anti-infective use was reduced throughout the high
reporting period, infection reports were only reduced in the
context of OSCS-mediated symptoms. Thus it is unlikely dilution
accounts for our observations. Adverse event reports are often
duplicated so the database we used has an electronic de-
duplication algorithm. Our data does not appear to differ notably
in terms of the major adverse events identified from either the
CDC study [4] or the manually de-duplicated database of heparin
adverse event reports [8].
As shown in figure 6, when BK is generated, levels are limited
due to degradation by three BK kininases, angiotensin-converting
enzyme (ACE), aminopeptidase P (APP) and carboxypeptidase N
(CPN), which cleave BK at the 7–8, 1–2, and 8–9 positions,
respectively [32,33,34]. Due to these enzymes, BK is usually
degraded within minutes after its generation and does not
accumulate [32]. In the kinin-kallikrein system, any shift of the
generation or degradation of BK can change levels of BK. A
recent study by Adam et. al. showed OSCS induction of BK in
ACEi treated human plasma [25]. This finding supports kallikrein
generation of BK as the mechanism for OSCS induced adverse
events and suggests that ACEi use could be another risk factor for
OSCS mediated adverse events. The CDC study [4] noted 26% of
patients with contaminated heparin mediated events were on
ACEi, a prevalence that did not appear to be greater than
expected. Our study did not find a meaningful increase in the
frequency of cases reporting ACEi use during the time period of
the OSCS contamination. Since ACEi blockade of BK degrada-
tion should lead to increased accumulation of BK, the lack of a
relationship between ACEi and adverse events needs explanation.
The use of ACEi may lead to compensatory increases in other
mechanisms to clear BK such as APP, CPN or other proteases.
ACEi associated angioedema only occurs in 0.1 to 1% of treated
patients suggesting a large fraction of treated patients have
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on ACEi angioedema suggests differences in induction of Des-Arg
BK instead of BK correlate with ACEi angioedema [36]. Although
compensatory mechanisms and kinin specificity may explain the
lack of an association of adverse events with ACEi, further
evaluation is needed.
Our observations regarding C1inh have broader implications
than OSCS contamination and infection. There are many other
potential causes of decreased C1inh. Although the genetic
deficiency of C1inh in humans, hereditary angioedema, is a very
rare life-threatening disorder [11,23,37,38], there may be some
asymptomatic patients who are missed, including relatives of
known cases [39]. Consumption of C1inh may occur in patients
with autoimmunity such as SLE [40,41,42,43]. Antibodies to C1
inh have been observed in some healthy individuals as well as SLE
patients [43] and such antibodies may predispose healthy
individuals to contact system stressors such as OSCS. Adaptive
C1inh deficiency can be observed in patients with B cell
lymphoma [21,44]. Some hormone products, such as estrogen
containing oral contraceptives may impact genetic C1 inh
deficiency as well as lead to a mild C1 inh deficiency in unaffected
individuals [39]. C1 inh decreases during open heart surgery [22]
and low C1 inh levels were correlated with capillary leak syndrome
in children undergoing cardiac bypass surgery [45]. Of note ,5%
of patients with heparin associated adverse events in the CDC
study [4] and 16% of heparin associated adverse events in the
AERS study [8] were linked to cardiac procedures.
It is likely that many inflammatory conditions can alter C1inh
levels through consumption or increased synthesis. Since these
opposing responses may occur together, functional C1inh levels
may be dynamic and differ over time in the same patient. Real-
time monitoring of C1inh activity may be useful in understanding
the dynamics of susceptibility to contact system triggers. Although
C1inh levels vary between patient populations, there is significant
variability within a population as seen in figure 5. This suggests
that in addition to all the individuals with defined pathological
states that alter C1 inh levels, there will be a subset of individuals
within the normal population who are more susceptible to contact
system triggers. Although we demonstrate a correlation between
lower levels of kallikrein generation and increased levels of
functional C1inh in patient samples, the limited correlation
suggests there are other important factors in addition to C1inh
levels. As the patho-physiology of sepsis or infectious disease is
complicated and may change multiple factors, the OSCS-induced
lower kallikrein production in septic patients might be a
consequence of combination of several parameters such as lower
prekallikrein and/or Factor XIIa levels [28] in addition to an
increased C1inh level. In addition, in the cases of sepsis, other
protease inhibitors, such as alpha-2-macroglobulin, may also
decrease [27]. It will be important to better understand the role of
other potential factors such as those shown in figure 6. A
combination of factors may fully explain the low rate of reported
events.
In conclusion, several types of data indicate that C1inh level is
likely to be an important factor in patient susceptibility to OSCS-
contaminated heparin. The totality of data from in vitro studies on
C1inh effects, evaluation of clinical samples and clinical adverse
event reports supports the relevance of C1 inhibitor as an
important factor. Although current analytics can detect future
OSCS contaminations, other contaminants and/or other products
may also trigger the contact system and lead to adverse events.
Understanding patient susceptibilities to contact system activation
may facilitate strategies to prevent such adverse events. For
example, with appropriate supportive clinical studies and regula-
tory approval, there may be a role for C1inh in therapy or
prevention when treatments with potential contact system
reactions are necessary.
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Figure 6. Factors that can influence bradykinin levels. The level of bradykinin (BK) is determined by the levels of kallikrein (KAL), high
molecular weight kininogen (HMWK) and enzymes that degrade BK, such a angiotensin converting enzyme (ACE), aminopeptidase P (APP) and
neutral carboxypeptidase (CPN). Activated factor XII (FXIIa) generates KAL from prekallikrein (PK). C1 inhibitor (C1inh) can inhibit both FXIIa and KAL.
OSCS can facilitate FXIIa activity through enhancing its generation from FXII and/or stabilizing a complex of FXIIa, PK and HMWK. OSCS may also have
a direct effect on C1inh. Other factors in the complement pathway and coagulation cascade can interact with C1inh and thus decrease C1inh
availability for limiting BK production.
doi:10.1371/journal.pone.0034978.g006
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